Pediapharm Inc.
TSX VENTURE : PDP

Pediapharm Inc.

April 23, 2015 16:56 ET

Pediapharm Inc. to Present at 2015 Bloom Burton & Co. Healthcare Investor Conference

MONTREAL, QUEBEC--(Marketwired - April 23, 2015) - Pediapharm Inc. ("Pediapharm" or the "Company") (TSX VENTURE:PDP) announced today that management is scheduled to present an overview of the Company at the 2015 Bloom Burton & Co. Healthcare Investor Conference at the Sheraton Centre Toronto Hotel on May 5, 2015 at 10:00 a.m. Eastern Time.

The Bloom Burton & Co. Healthcare Investor Conference brings together U.S., Canadian and international investors who are interested in the latest developments in the Canadian healthcare sector. Attendees will have an opportunity to obtain corporate updates from the premier Canadian publicly traded and private companies through presentations and private meetings.

About Pediapharm Inc.

Pediapharm is the only Canadian specialty pharmaceutical company dedicated to serving the needs of the pediatric community. Its mission is to bring to the Canadian market the latest innovative pediatric products with the objective to improve the health and the well-being of children in Canada. Since its debut in 2008, Pediapharm has entered into numerous commercial agreements with partners from Canada and other countries around the world. The Company's innovative portfolio of commercialized products includes NYDA®, a breakthrough treatment for head lice; Pediapharm Naproxen Suspension, the only prescription NSAID available in Canada; EpiCeram®, a non-steroid emulsion for eczema; KoolEffect® which reduces the symptoms of fever; and VapoLyptus®, a soothing vapour patch of Eucalyptus and Camphor.

For more information about Pediapharm or its products, please visit www.pedia-pharm.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information